Daxor Corporation announced the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure (ADHF) utilizing the BVA-100 blood test. Over 6 million Americans suffer from heart failure, one of the most prevalent and deadly diseases leading to nearly 1 million deaths and 1 million hospitalizations annually. The study’s primary objective is to determine the benefit of goal-directed care guided by Daxor’s blood volume measurement system, in addition to usual care, resulting in more appropriate treatment and consistent achievement of optimal blood volume.